BCAB

BioAtlaC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

Current thesis

The constructive case is that BCAB still has monetizable assets and management is actively pursuing licensing, partnership, sale, or other strategic paths while cutting costs to extend runway [#SEC-8K-2026-03-31].

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite.

What can break

Clinical development could be delayed or narrowed as management preserves capital.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $3.50 · Bull $5.25 · Bear $1.50

Data freshness

Prices

As of 2026-07-21

Fundamentals

As of 2026-07-21 • Vendor: Data Vendor v1

Scores

As of 2026-07-21 • Model: HYBRID_IC_RP

AI Memo

As of 2026-06-17 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-21

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $52.00

Why

Momentum88 · Δ7d -

Value41 · Δ7d +0.1

Sentiment38 · Δ7d -

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

39% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

-0.0

Sentiment

34% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade C. Momentum 87.9 / Value 41.1 / Sentiment 37.8

Fundamentals (TTM)

As of 2026-07-21

Market Cap

$6.12M

Beta

1.11

Shares Out

1.66M

P/E (TTM) · Derived

-0.1

P/S (TTM)

4.22

P/FCF (TTM) · Derived

-3.64

Rev YoY

-100.0%

EPS YoY

-67.9%

Gross Margin

+84.5%

Op Margin

-579.8%

Net Debt

$3.22M

Current Ratio

0.15

As of 2026-07-21 • Updated nightlySource: Internal modelMethodology